Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
In alignment with the Trump administration’s efforts to lower drug prices, Amgen today launched AmgenNow, a direct-to-patient program offering evolocumab (Repatha) at a monthly price of $239, nearly ...
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, ...
Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
Amgen launches AmgenNow, offering Repatha at 60% off as part of Trump’s push for direct-to-consumer drug sales aimed at ...
Asianet Newsable on MSN
Amgen To Sell Cholesterol Drug For Approximately 60% Discount
A mgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current ...
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced ...
GoodRx, an online platform that offers drug discount coupons to patients, is in talks with the government to participate in ...
8don MSN
Oppenheimer Highlights Amgen’s (AMGN) Strong Revenue Growth and Breakthrough in Cardiovascular Study
On October 3, Oppenheimer reaffirmed its Outperform rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $380.
Q. A renowned senior cardiologist in our area has been taking all his patients off statins and putting them on Repatha. He did this for my husband, and the results have been amazing. Within three ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback